email article
Standard chemotherapy and high-dose chemotherapy plus autologous stem cell transplant (ASCT) led to similar disease control after first relapse of early-stage, favorable, classic Hodgkin lymphoma, pooled data from two clinical trials showed.
After adjustment for confounding factors, second progression-free survival (PFS) did not differ significantly between patients treated with standard chemotherapy or ASCT (HR 0.70, 95% CI 0.3-1.6,
P=0.39). Subgroup analyses showed that patients younger than 60 had numerically superior 2-year second PFS (94.0% vs 83.3%) and overall survival (OS, 97.2% vs 88.4%) with chemotherapy, Paul J. Bröckelmann, MD, of University Hospital Cologne in Germany, and co-authors reported in the Relapse mostly occurs more than 12 months after initial diagnosis and with stage I-II disease, they concluded. Physicians choice CTx [chemotherapy] . is frequently applied as second-line therapy and is associated with similar second PFS and OS,
Alberta expanding rapid testing to better track cases in vulnerable populations.
As COVID-19 cases rise in much of the country, cancer specialists worry about the drop in screening numbers and potential undetected illnesses.
Read more: A ski resort in British Columbia fires employees after a rash of virus cases linked to parties; find out how many entries into Canada there have been since the pandemic began and the challenges for border officials.
Dr. Georg Siemon looks out of a traditional small Frankfurt kiosk on Thursday. The German doctor offers COVID-19 tests with a result in 20 minutes at the kiosk. (Michael Probst/The Associated Press)
Oncologist fears tsunami of cancer after COVID-19 lockdowns limited screening
Cancer specialists are worried about the significant drop in cancer screening, referrals and diagnoses in Canada since the pandemic began in March. It doesn t mean cancer rates are dropping it means people with cancer don t know it yet.
Social Sharing
December 11, 2020 – Smutty Shout-Outs laineygossip.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from laineygossip.com Daily Mail and Mail on Sunday newspapers.
WINNIPEG CAR-T cancer treatments are proving to be revolutionary for some patients who may not have any treatment options left. Winnipegger Bob Plamondon is proof. At the end of 2017, he was diagnosed with large b-cell lymphoma, an aggressive form of blood cancer. He said he did three rounds of chemotherapy, with no success. “They couldn’t do any more for me so they put me on palliative care,” he said. In June of 2018, he said his doctor suggested he try CAR-T therapy, but he would need to travel to the Mayo Clinic in the U.S. to get it.